36.9 F
New York
Friday, January 22, 2021

MediciNova [NASDAQ: MNOV] Strikes Deal With BioComo And Mie University For SARS-CoV-2 Vaccine Development

Must read

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...

Shutterstock [NYSE: SSTK] To Extend Its Agreement With EPA

Shutterstock reported that the company renewed its exclusive contract with the European Pressphoto Agency. The extended contract is to distribute the visual content...

MediciNova, Inc. [NASDAQ: MNOV] inked a deal to co-develop the SARS-CoV-2 vaccine with Mie University of Japan & BioComo. MediciNova will develop the COVID-19 vaccine using the human parainfluenza virus type 2 vector, BC-PIV.

BC-PIV is being developed by Mie University & BioComo. BC-PIV has been derived from hPVI2 and it is a non-communicable viral vector. It has the ability to pass on multiple foreign proteins to recipients. BC-PIV is also very safe as no other infectious virus is developed.

It has the ability to carry the large membrane proteins of viruses & signal transduction receptors protein on the surface of the virus. It is developed in a way that it not only display the gene but also exhibits foreign protein itself on the surface & inside the viral membrane.

The SARS-CoV-2 vaccine sample has been created to include the specific SARS-CoV-2 antigen protein in order to show maximum antigenicity. The firm has already got the right to use the BC-PIV for the development of the SARS-CoV-2 vaccine from Mie University & BioComo.

MediciNova, Inc. shares had tumbled 2.08% at $5.64 during the trading of Friday. It had a trading volume of rougly 49k and an average volume of 128.29k. If we look at its profitability, it has return on assets of -14.10%, return on equity of -14.80%.

MediciNova, Inc has recorded the current ratio of 34.60. Likewise, its quick ratio s 34.60. In the past 52-weeks of trading, this company’s stocks has changed between the 52-weeks low of $2.79 and a high of $9.95. It has moved up 102.15% from its 52-weeks low and moved down -43.33% from its 52-weeks high.

President and Chief Executive Officer of MediciNova, Inc, Yuichi Iwaki, M.D., Ph.D. said that the COVID-19 pandemic has spread all around and this is a great opportunity for the company to co-develop the vaccine with BioComo and Mie University.

BioComo had developed the vaccines for Ebola virus and RS virus using the BC-PIV technology. MediciNova is confident that this BC-PIV technology will also be successful in the development of the SARS-CoV-2 vaccine. Furthermore, it is very attractive that a BC-PIV SARS-CoV-2 vaccine can be made as an intranasal formulation.  

More articles

Latest article

Tencent Music [NYSE: TME] To Purchase 100% Equity Interest Of Lazy Audio

Tencent Music Entertainment Group reported that the company has signed a contract to purchase 100 percent shares of Lazy Audio. Lazy audio is...

Desktop Metal [NYSE: DM] Inks Agreement To Purchase EnvisionTEC

Desktop Metal reported that the company inked a definitive contract to purchase EnvisionTEC. Desktop Metal will purchase EnvisionTEC for a total consideration of...

Sequential Brands [NASDAQ: SQBG] Partnered With Omega Apparel To Create A New Collection

Sequential Brands Group reported that the company has collaborated with Omega Apparel for its denim business. With this partnership, the company will develop...

Marathon Petroleum [NYSE: MPC] Appoints New CFO

Marathon Petroleum Corp. reported that the company has named Maryann T. Mannen as the CFO and Executive V.P of the company. Maryann has...

QUALCOMM [NASDAQ: QCOM] Announces To Purchase NUVIA For $1.4Billion

QUALCOMM Incorporated reported that its unit, Qualcomm technologies inked a contract to purchase NUVIA.  The company will purchase NUVIA for nearly $1.4B. The...

Trivago [NASDAQ: TRVG] Reported The Purchase Of Weekend.com

Trivago reported that the company has purchased Weekend.com. Weekend it just started based in Germany, its main aim is to provide stimulating getaway...

Arthur J. Gallagher [NYSE: AJG] Reports To Purchase 100% of The Bollington Wilson Group

Arthur J. Gallagher reported that the company has inked a contract to buy 100% of the Bollington Wilson group. Bollington is an insurance...

Grainger [NYSE: GWW] Reports Changes In The Executive Leadership

Grainger reported changes in its Executive leadership. The leading supplier and distributor of MRO products appointed Deidra Merriwether as the Chief Financial officer....